Tigermed hones in on $1.4bn HK secondary listing

Jonathan Breen

July 27, 2020 08:45 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Hangzhou Tigermed Consulting, a biopharmaceutical research and development service provider, has covered books on its secondary public offering in Hong Kong on the first day of taking orders.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

CITIC Securities Credit Suisse Equity IPOs UBS Equity China Merchants Bank Co China Bank of America China International Capital Corp Jefferies LLC Hong Kong SAR ICBC Asia Greater China Haitong Securities Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia